Last reviewed · How we verify
Imiquimod and Interferon alpha
Imiquimod activates toll-like receptors to stimulate innate immunity, while interferon alpha enhances antiviral and anti-tumor immune responses through multiple signaling pathways.
Imiquimod activates toll-like receptors to stimulate innate immunity, while interferon alpha enhances antiviral and anti-tumor immune responses through multiple signaling pathways. Used for Melanoma, Viral infections, Cutaneous malignancies.
At a glance
| Generic name | Imiquimod and Interferon alpha |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Immunostimulant combination |
| Target | TLR7/8 (imiquimod); Interferon-alpha receptor (interferon alpha) |
| Modality | Biologic |
| Therapeutic area | Oncology; Immunology |
| Phase | FDA-approved |
Mechanism of action
Imiquimod is a TLR7/8 agonist that promotes dendritic cell maturation and Th1 immune responses. Interferon alpha binds to interferon-alpha receptors on immune and tumor cells, enhancing natural killer cell activity, macrophage activation, and antigen presentation. Together, this combination amplifies both innate and adaptive immune responses against target cells.
Approved indications
- Melanoma (investigational combination therapy)
- Basal cell carcinoma (imiquimod approved topically; combination investigational)
Common side effects
- Local skin reactions (erythema, erosion, scabbing)
- Flu-like symptoms (fever, fatigue, myalgia)
- Systemic immune activation effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |